HK Stock Market Move | ASCENTAGE-B(06855) up over 5% again, the company will welcome multiple milestones and catalyst events this year.

ASCENTAGE-B (06855) rose by over 5%, as of the time of writing, it has increased by 5.37% to 45.88 Hong Kong dollars, with a turnover of 55.0621 million Hong Kong dollars. On the news front, at the end of February, Ascend Pharmaceuticals registered a phase I clinical trial of BTK PROTAC new drug APG-3288 in the United States for the treatment of recurrent or refractory hematologic malignancies. It is reported that the company will see multiple milestones and catalyst events in 2026, such as continuing to advance the clinical enrollment of GLORA, completing most of the enrollment work for GLORA-4, advancing the clinical enrollment of POLARIS-2, completing most of the enrollment work for POLARIS-1, and conducting a global phase I clinical trial of APG-3288.